Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Outlook Therapeutics Inc (OTLKW)

Outlook Therapeutics Inc (OTLKW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference GlobeNewswire - Mon Nov 24, 8:05AM CST

ISELIN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 2.03 (-3.11%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD GlobeNewswire - Thu Nov 13, 7:30AM CST

Prescription Drug User Fee Act (PDUFA) goal date of December 31, 2025 ISELIN, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused...

OTLK : 2.03 (-3.11%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 GlobeNewswire - Mon Nov 3, 7:35AM CST

ISELIN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of...

OTLK : 2.03 (-3.11%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Provides Update on Type A Meeting with FDA GlobeNewswire - Mon Sep 29, 7:45AM CDT

ISELIN, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.   (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment...

OTLK : 2.03 (-3.11%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Requests Type A Meeting with FDA GlobeNewswire - Tue Sep 2, 7:35AM CDT

ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment...

OTLK : 2.03 (-3.11%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD GlobeNewswire - Thu Aug 28, 5:30AM CDT

FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLA Outlook Therapeutics plans to work with FDA to address the Agency’s issues Company to host a conference call and webcast today,...

OTLK : 2.03 (-3.11%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update GlobeNewswire - Thu Aug 14, 7:05AM CDT

First commercial sales of LYTENAVA™ (bevacizumab gamma) achieved in Europe ONS-5010/LYTENAVA™ (bevacizumab-vikg) Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, in the United...

OTLK : 2.03 (-3.11%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase GlobeNewswire - Thu Jul 24, 8:00AM CDT

ISELIN, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 2.03 (-3.11%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference GlobeNewswire - Tue Jul 22, 7:45AM CDT

Video webcast now available on-demand ISELIN, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard...

OTLK : 2.03 (-3.11%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer GlobeNewswire - Tue Jul 1, 7:05AM CDT

OTLK : 2.03 (-3.11%)
OTLKW : 0.03 (-1.96%)

Barchart Exclusives

Should You Buy Micron Before December 17? These Analysts Think So. Barchart - 6 minutes ago
Micron’s upcoming earnings report is drawing intense attention as Wall Street turns increasingly bullish. Is now the time to buy its shares? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot